Hyperhomocysteinemia: A risk factor for cardiovascular disease … Influence of sex hormones on homocysteine metabolism

Gynecological Endocrinology

Volumn 10, Issue sup2, 1996, Pages 75-79

  Blom, H J ^a   Van Der Moorent, M J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cardiovascular Disease; Homocysteine Metabolism; Oral Contraceptives

Indexed keywords

EID: 0002924335     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513599609045633     Document Type: Article

References (39)

1. Mudd S. H., Levy H. L., Skovby F. Disorders of transsulfuration. The Metabolic Basis of Inherited Disease, 6th edition, C. R. Scriver, A. L. Beaudet, W. S. Sly, D. Valle. McGraw-Hill, New York 1989; 693 – 734
2. Rosenblatt D. S. Inherited disorders of folate transport and metabolism. The Metabolic Basis of Inherited Disease, 6th edition, C. R. Scriver, A. L. Beaudet, W. S. Sly, D. Valle. McGraw-Hill, New York 1989; 2049 – 64
3. Kraus J. P. Molecular basis of phenotype expression in homocystinuria. J. Inher. Metab. Dis. 1994; 17: 383 – 90
4. Kluijtmans L. A.J., Blom H. J., Boers G. H.J., VanOost B. A., Trijbels J. M.F., Vanden Heuvel L. P.W.J. Two novel missense mutations in the cystathonine β-synthase gene in homocystinuric patients. Hum. Genet. 1995; 96: 249 – 50
5. Goyette P., Frosst P., Rosenblatt D. S., Rozen R. Seven novel mutations in the methylenetetrahydrofolate reductase gene and genotype/phenotype correlations in severe methylenetetrahydrofolate reductase deficiency. Am. J. Hum. Genet. 1995; 56: 1052 – 9
6. McCully K. S. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am. J. Pathol. 1969; 56: 111 – 28
7. Boers G. H.J., Smals A. G. H., Trijbels J. M.F., Fowler B., Bakkeren J. A. J. M., Schoonderwaldt H. C., Kleijer W. J., Kloppenborg P. W.C. Heterozygosity for homocystinuria in peripheral and cerebral occlusive arterial disease. N. Engl. J. Men. 1985; 313: 709 – 15
8. Clarke R., Daly L., Robinson K., Naughten E., Cahalane S., Fowler B., Graham I. Hyperhomocysteinemia: an independent risk factor for vascular disease. N. Engl. J. Med. 1991; 324: 1149 – 55
9. Ueland P. M., Refsum H., Brattstrom L. Plasma homocysteine and cardiovascular disease. Artherosclerotic Cardiovascular Disease, Hemostasis and Endothelial Function, R. B. Francis. Marcel Dekker Inc., New York 1992; 183 – 236
10. DenHeijer M., Blom H. J., Gerrits W. B.J., Rosendaal F. R., Bos G. M.J. Hyperhomocysteinemia: a risk factor for recurrent venous thrombosis. Lancet 1995; 345: 882 – 5
11. Wouters M. G.A.J., Boers G. H.J., Blom H. J., Trijbels J. M.F., Thomas C. M.G., Borm G. F., Steegers-Theunissen R. P. M., Eskes T. K.A.B. Hyperhomocysteinemia: a risk factor in women with unexplained recurrent early pregnancy loss. Fertil. Steril. 1993; 60: 820 – 5
12. Vander Put N. J.M., Steegers-Theunissen R. P.M., Frosst P., Trijbels J. M.F., Eskes T. K.A.B., Vanden Heuvel L. P., Mariman E. C.M., DenHeijer M., Rozen R., Blom H. J. Mutated methylenetetrahydrofolate reductase as a risk-factor for spina bifida. Lancet 1995; 246: 1070 – 2
13. Finkelstein J. D. Methonine metabolism in mammals. J. Nutr. 1990; 1: 228 – 37
14. Mudd S. H., Havlik R., Levy H. L., McKusick V. A., Feinleib M. A study of cardiovascular risk in heterozygotes for homocystinuria. Am. J. Hum. Genet. 1981; 33: 883 – 93
15. Daly L., Robinson K., Tan K. S., Graham I. Hyperhomocysteinemia: a metabolic risk factor for coronary heart disease determined by both genetic and environmental influences. Q. J. Med. 1993; 86: 685 – 9
16. Engbersen A. M. T., Franken D. G., Boers G. H.J., Stevens E. M. B., Trijbels J. M.F., Blom H. J. Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia. Am. J. Hum. Genet. 1995; 56: 142 – 50
17. Kluijtmans L. A.J., Vanden Heuvel L. P.W.J., Boers G. H.J., Frosst P., VanOost B. A., DenHeijer M., Stevens E. M. B., Trijbels J. M.F., Rozen R., Blom H. J. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am.J. Hum. Grnet.
18. Kozich V., Kraus E., DeFranchis R., Fowler B., Boers G. H.J., Graham I., Kraus J. P. Hyperhomocysteinemia in premature arterial disease: examination of cystathionine β-synthase alleles at the molecular level. Hum. Mol. Genet. 1995; 4: 623 – 9
19. Kang S. S., Wong P. W. K., Susmano A., Sora J., Norusis M., Ruggie N. Thermolabile methylenetetrahydrofolate reductase: an inherited risk factor for coronary artery disease. Am. J. Hum. Genet. 1991; 48: 536 – 45
20. Frosst P., Blom H. J., Milos R., Goyette P., Sheppard C. A., Matthews R. G., Boers G. H.J., DenHeijer M., Kluijtmans L. A.J., Vanden Heuvel L. P., Rozen R. Identification of a candidate genetic risk factor for vascular disease: a common mutation at the methylenetetrahydrofolate reductase locus. Nature Genet. 1995; 10: 111 – 13
21. Mudd S. H., Skovby F., Levy H., et al. The natural history of homocystinuria due to cystanthionine β-synthase deficiency. Am. J. Hum. Genet. 1985; 37: 1 – 31
22. Franken D. G., Boers G. H.J., Blom H. J., Trijbels J. M.F., Kloppenborg P. W.C. Treatment of mild hyperhomocysteinemia in vascular disease patients. Arterioscler. Thromb. 1994; 14: 465 – 70
23. Brattström L., Israelsson B., Norrving B., Bergqvist D., Thörne J., Hultberg B., Hamfelt A. Impaired homocysteine metabolism in early-onset cerebral and peripheral occlusive arterial disease. Effects of pyridoxine and folic acid treatment. Atherosclerosis 1990; 81: 51 – 60
24. Boers G. H.J., Smals A. G. H., Trijbels J. M.F., Leermakers A. I., Kloppenborg P. W. Unique efficiency of methionine metabolism in premenopausal women may protect against vascular disease in the reproductive years. J. Clin. Invest. 1983; 72, 1971-6
25. Blom H. J., Boers G. H.J., Van den Elzen J. P. A. M., Van Roessel J. J.M., Trijbels J. M.F., Tangerman A. Differences between premenopausal women and young men in the transamination pathway of methionine catabolism, and the protection against vascular disease. Eur. J. Clin. Invest. 1988; 18: 633 – 8
26. Kang S. S., Wong P. W. K., Zhou J., Cook H. Y. Total homocyst(e)ine in plasma and amniotic fluid of pregnant women. Metabolism 1986; 35: 889 – 91
27. Andersson A., Hultberg B., Brattstrom L., Isaksson A. Decreased serum homocysteine in pregnancy. Eur. J. Clin. Chem. Clin. Biochem. 1992; 30: 377 – 9
28. Brattström L. E., Hultberg B. L., Hardebo J. E. Folic acid responsive postmenopausal homocysteinaemia. Metabolism 1985; 34: 1073 – 7
29. Kang S. S., Wong P. W. K., Cook H. Y., Norusis M., Messer J. V. Protein-bound homocyst(e)ine: a possible risk factor for coronary artery disease. J. Clin. Invest. 1986; 77: 1482 – 6
30. Anderson A., Brattstrom L., Israelsson B., Isaksson A., Hamfelt A., Hultberg B. Plasma homocysteine before and after methionine loading with regard to age, gender, and menopausal status. Eur. J. Clin. Invest. 1992; 22: 79 – 87
31. Dudman N. P. B., Wilcken D. E. L., Wang J., Lynch J. F., Macey D., Lundberg P. Disordered methionine/homocysteine metabolism in premature vascular disease. Its occurrence, cofactor therapy, and enzymology. Arterioscler. Thromb. 1993; 13: 1253 – 60
32. Wouters M. G. A. J., Moorrees M. T. E. C., Van der Mooren M. J., Blom H. J., Boers G. H.J., Schellekens L. A., Thomas C. M. G., Eskes T. K.A.B. Plasma homocysteine and menopausal status. Eur. J. Clin. Invest.
33. Steegers-Theunissen R. P.M., Boers G. H.J., Steegers E. A.P., Trijbels J. M.F., Thomas C. M.G., Eskes T. K.A.B. Effects of sub-50 oral contraceptives on homocysteine metabolism: a preliminary study. Contraception 1992; 45: 129 – 39
34. Brattström L., Israelsson B., Olsson A., Anderson A., Hultberg B. Plasma homocysteine in women on oral oestrogen-containing contraceptives and in men with oestrogen-treated prostatic carcinoma. Scand. J. Clin. Lab. Invest. 1992; 52: 283 – 7
35. Van der Mooren M. J., Wouters M. G. A. J., Blom H. J., Schellekens L. A., Eskes T. K. A. B., Rolland R. Hormone replacement therapy may reduce high serum homocysteine in postmenopausal women. Eur. J. Clin. Invest. 1994; 24: 733 – 6
36. Van der Mooren M. J., Wouters M. G.A.J., Blom H. J., Schellekens L. A., Eskes T. K.A.B., Rolland R. Homocysteine concentrations may decrease during postmenopausal hormone replacement therapy. Ir. J. Med. Sci. 1995; 164 (Suppl. 15) 21
37. Stampfer M. J., Colditz G. A. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev. Med. 1991; 151: 75 – 8
38. Anker G., Lønning P. E., Ueland P. M., Refsum H., Lien E. A. Plasma levels of the atherogenic amino acid homocysteine in postmenopausal women with breast cancer treated with tamoxifen. Int. J. Cancer 1995; 60: 365 – 8
39. Rutquist L. E., Mattson A. Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. J. Nut. Cancer Inst. 1993; 85: 1398 – 406